Operator: Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter ...

TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.37 per share a year ago. These ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

B. Riley notes TG Therapeutics (TGTX) reported Q3 results, pointing to strong 15% sequential quarter-over-quarter growth in Briumvi U.S. sales, ...

Ladenburg raised the firm’s price target on TG Therapeutics (TGTX) to $45 from $43 and keeps a Buy rating on the shares. The company reported strong Briumvi revenue in Q3, the analyst tells investors ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.